OUTCOME OF AUTOLOGOUS STEM CELL TRANSPLANTATION IN MULTIPLE MYELOMA; EXPERIENCE FROM A SINGLE CENTER IN SAUDI ARABIA
Sign Up to like & getrecommendations! Published in 2019 at "Hematological Oncology"
DOI: 10.1002/hon.240_2631
Abstract: del17p – 5.6% (9/159); 1p32/1q21 amp/del – 12% (19/159); hypodiploidy – 3.1% (5/159); hyperdiploidy – 1.25% (2/159); del5q – 0,6% (1/159); other – not found. Combination two aberrations was discovered in 11.9% (19/159) patients, complex… read more here.
Keywords: risk; risk msmart; median pfs; complex abnormalities ... See more keywords
938PDPrognostic relevance of immune-related gene expression signatures (irGES) in patients (pts) with ovarian clear cell carcinomas (OCCC)
Sign Up to like & getrecommendations! Published in 2017 at "Annals of Oncology"
DOI: 10.1093/annonc/mdx372.008
Abstract: Results: Total of 74/84 samples were successfully profiled. Median age at diagnosis was 53 yrs. 41 (55.4%) were stage 1, 7 (9.5%) stage 2, 24 (32.4%) Stage3, 2 (2.7%) stage 4. 64/74 (86.5%) of pts… read more here.
Keywords: cell; median pfs; stage pts; expression ... See more keywords
Alliance A091902: A multicenter randomized phase II trial of paclitaxel (P) with or without nivolumab (N) in patients (pts) with advanced angiosarcoma (AS).
Sign Up to like & getrecommendations! Published in 2024 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2024.42.16_suppl.11514
Abstract: 11514 Background: The role of immunotherapy remains uncertain in most sarcomas. We recently showed significant antitumor benefit for cabozantinib (C) with N in AS previously treated with a taxane. Since chemotherapy-immunotherapy combinations may synergize, and… read more here.
Keywords: paclitaxel; arm; trial; median pfs ... See more keywords
Efficacy and safety of eribulin plus gemcitabine in second-line or beyond for patients with HER2-negative metastatic breast cancer (MBC): A multicenter, open-label, single-arm, phase II study.
Sign Up to like & getrecommendations! Published in 2024 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2024.42.16_suppl.e13139
Abstract: e13139 Background: The combination of eribulin and gemcitabine has demonstrated a similar progression-free survival (PFS) benefit as paclitaxel plus gemcitabine, with less neurotoxicity, for patients with MBC who have not received prior cytotoxic chemotherapy. However,… read more here.
Keywords: mbc; median pfs; second line; plus gemcitabine ... See more keywords
Real-world data analysis of first-line targeted therapy for patients with non-small cell lung cancer with different EGFR mutation status in a tertiary care hospital.
Sign Up to like & getrecommendations! Published in 2024 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2024.42.16_suppl.e20586
Abstract: e20586 Background: Lung cancer is still the malignant tumor with the highest incidence and mortality rate in the world, of which non-small cell lung cancer (NSCLC) accounts for about 85%. The EGFR mutation rate in… read more here.
Keywords: egfr mutation; first line; line targeted; mutation ... See more keywords
A phase 2 study of regorafenib in metastatic/unresectable, refractory synovial sarcomas.
Sign Up to like & getrecommendations! Published in 2024 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2024.42.16_suppl.e23551
Abstract: e23551 Background: Current therapeutic options for advanced synovial sarcomas remain limited. Adoptive T-cell therapies against NY-ESO-1 and MAGE-4 benefit a subset of patients, but is of limited value in Asian patients due to the absence… read more here.
Keywords: quality life; sarcomas; synovial sarcomas; median pfs ... See more keywords
Trends in endpoint use in pivotal trials and efficacy for US Food and Drug Administration-approved solid tumor therapies, 1995-2021.
Sign Up to like & getrecommendations! Published in 2022 at "Journal of managed care & specialty pharmacy"
DOI: 10.18553/jmcp.2022.28.11.1219
Abstract: BACKGROUND: Many cancer therapies are now approved based on surrogate endpoints such as progression-free survival (PFS) to ensure that patients have speedy access to life-saving cancer medicines. However, the link between surrogate endpoints and overall… read more here.
Keywords: oncology; median pfs; pfs; 1995 2021 ... See more keywords
Efficacy and safety of anlotinib in patients with advanced non-small cell lung cancer.
Sign Up to like & getrecommendations! Published in 2020 at "Journal of thoracic disease"
DOI: 10.21037/jtd-20-2855
Abstract: Background Non-small cell lung cancer (NSCLC) is the most common type of lung cancer and its incidence seriously affects human health. The purpose of this study was to evaluate the efficacy and safety of anlotinib… read more here.
Keywords: median pfs; advanced nsclc; lung cancer; patients advanced ... See more keywords
Efficacy of First Line Systemic Chemotherapy and Multikinase Inhibitors in Advanced Hepatocellular Carcinoma: A Systematic Review and Network Meta-Analysis
Sign Up to like & getrecommendations! Published in 2021 at "Frontiers in Oncology"
DOI: 10.3389/fonc.2021.654020
Abstract: Background Hepatocellular carcinoma (HCC) is the third most fatal cancer, with a 5-year survival rate of 18%. Standard frontline-therapy is multikinase inhibitors (MKIs), but accessibility is still limited, particularly in developing countries. This network meta-analysis… read more here.
Keywords: hepatocellular carcinoma; pfs months; median pfs; multikinase inhibitors ... See more keywords
Eighteen years’ experience with tumor treating fields in the treatment of newly diagnosed glioblastoma
Sign Up to like & getrecommendations! Published in 2023 at "Frontiers in Oncology"
DOI: 10.3389/fonc.2022.1014455
Abstract: Introduction The prognosis of glioblastoma remains unfavorable. TTFields utilize low intensity electric fields (frequency 150–300 kHz) that disrupt cellular processes critical for cancer cell viability and tumor progression. TTFields are delivered via transducer arrays placed… read more here.
Keywords: median pfs; glioblastoma; treated ttfields; newly diagnosed ... See more keywords